 Randomized, open, Phase II-III study, comparative between treatment with CSF-470 vaccine , allogeneic, irradiated with BCG and molgramostin rHuGM-CSF as adjuvants and interferon alfa 2b IFN-alpha2b treatment , in stages IIB, IIC o III AJCC post-surgery cutaneous melanoma patients. This study has been approved by ANMAT Administración Nacional de Medicamentos, Alimentos y Tecnología Médica ANMAT, number 15562011 